Ultragenyx Pharma up after JPMorgan PT raise

Shares of drugmaker Ultragenyx Pharmaceutical RARE.O rise 2% to $38.75

JPMorgan raises RARE's target price to $117 from $104

Believes RARE is uniquely positioned in the long term with a broad and diverse pipeline of orphan disease assets and a highly regarded management team - JPMorgan

19 of 20 brokerages rate the stock "buy" or higher, one "hold"; their median PT is $87, according to data compiled by LSEG

Up to last close, stock had fallen ~10% YTD